76 episodes

According to the American Cancer Society, yearly deaths from cancer are decreasing— marking the first period of decline in nearly 70 years. ReachMD takes a closer look at the driving forces behind these advances: medications that hone in on specific tumor targets, more accurate screening and diagnostic technologies, and pioneering surgical methods that provide new hope for patients suffering from these devastating diseases.

Focus on Cancer ReachMD

    • Science

According to the American Cancer Society, yearly deaths from cancer are decreasing— marking the first period of decline in nearly 70 years. ReachMD takes a closer look at the driving forces behind these advances: medications that hone in on specific tumor targets, more accurate screening and diagnostic technologies, and pioneering surgical methods that provide new hope for patients suffering from these devastating diseases.

    Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines

    Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines

    Host: John J. Russell, MD

    Guest: Richard Wender, MD


    From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations.
    For more information and to review the new guidelines, go to cancer.org

    FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

    FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

    Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
    Released on December 21, 2017

    CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer

    CAR-T Cell Therapy: A Breakthrough Treatment for Fighting Cancer

    Host: Shira Johnson, MD

    Guest: Robert Vonderheide, MD


    For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer.
    But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well.
    Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.

    Pancreatic Cancer: The Hunt to Catch a Silent Killer

    Pancreatic Cancer: The Hunt to Catch a Silent Killer

    Host: John J. Russell, MD

    Guest: Harish Lavu, MD


    Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations.
    Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the diagnostic and therapeutic priorities addressing pancreatic cancer, and why this disease is so hard to detect.

    FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

    FDA D.I.S.C.O.: Osimertinib for Non-Small Cell Lung Cancer

    FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
    Released July 28, 2017

    FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

    FDA D.I.S.C.O.: Two Approvals for ALK-Positive Non-Small Cell Lung Cancer

    FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
    Released July 25, 2017

Listeners Also Subscribed To